TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 341944

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mianserin 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg + Alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mianserin 10 mg + Alcohol
Number of subjects: 20
Study: 31783854

Group type: EXPERIMENTAL
Intervention: Electronic point-of-care reminders
Number of subjects: 328728

Group type: COMPARATOR
Intervention: Monthly feedback
Number of subjects: 328728

Group type: EXPERIMENTAL
Intervention: Screening for diabetic retinopathy
Number of subjects: 328728

Group type: EXPERIMENTAL
Intervention: Measurement of glycated hemoglobin
Number of subjects: 328728

Group type: EXPERIMENTAL
Intervention: Smoking cessation encouragement
Number of subjects: 328728
Study: 28173780

Group type: EXPERIMENTAL
Intervention: Internet-administered intervention (6-month access)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Care-as-usual/waitlist (CAU/WL) control group
Number of subjects: 200
Study: 25884350

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administered within 1 hour before skin incision
Number of subjects: 464

Group type: COMPARATOR
Intervention: Prophylactic antibiotics administered after skin incision
Number of subjects: 464
Study: 23986159

Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.005% (50 mcg/gm) applied twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coal tar 6% and salicylic acid 3% ointment applied at nighttime
Number of subjects: 60
Study: 22390816

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with tacrolimus monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy
Number of subjects: 0
Study: 19395556

Group type: EXPERIMENTAL
Intervention: CRT device switched on
Number of subjects: 33

Group type: COMPARATOR
Intervention: CRT device switched off
Number of subjects: 33
Study: 17848796

Group type: EXPERIMENTAL
Intervention: Individualized aerobic exercise training combined with conventional spa therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Spa therapy alone
Number of subjects: 44
Study: 14766772

Group type: EXPERIMENTAL
Intervention: Antioxidants (all‐rac‐alpha‐tocopherol 800 mg/day for 3 weeks and alpha‐lipoic acid 600 mg/day for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 12
Study: 11354934

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 13 weeks
Number of subjects: 501

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily, fluoxetine 90 mg weekly, or placebo during continuation therapy
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Continuation treatment (Fluoxetine 20 mg daily, fluoxetine 90 mg weekly)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Fluoxetine (any dosage)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Patients reporting worsening sexual function
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Overall sexual function
Number of subjects: 501
Study: 9741610

Group type: EXPERIMENTAL
Intervention: Exercise (3 supervised 45-min sessions per week for 12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Contact control (3 health education lectures/discussions per week for 12 weeks)
Number of subjects: 18
Study: 8150114

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate (200 micrograms twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Leuprolide acetate (1 mg/d SC)
Number of subjects: 24
Study: 3277925

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 29380251

Group type: EXPERIMENTAL
Intervention: Adalimumab 40-mg every week (EW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab 40-mg every other week (EOW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab for non-dermatologic indications (including Crohn's disease, ulcerative colitis, and rheumatoid arthritis)
Number of subjects: 0
Study: 27281802

Group type: EXPERIMENTAL
Intervention: Daily snack made from leafy green vegetables, fruit, and milk
Number of subjects: 2291

Group type: COMPARATOR
Intervention: Low-micronutrient vegetables (e.g., potato and onion)
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Treatment group (leafy green vegetables, fruit, and milk)
Number of subjects: 2291
Study: 24103040

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 145)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (n = 108)
Number of subjects: 253
Study: 23904825

Group type: EXPERIMENTAL
Intervention: External tube drainage (ETD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omentoplasty (OP)
Number of subjects: 50
Study: 20551163

Group type: EXPERIMENTAL
Intervention: Food color additive and sodium benzoate mixtures in a fruit drink (intervention group)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 297
Study: 18503925

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (CII)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intermittent subcutaneous insulin therapy
Number of subjects: 200
Study: 15567882

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.75 mg given 24 h apart
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Levonorgestrel 0.75 mg given 12 h apart
Number of subjects: 2018
Study: 12786681

Group type: EXPERIMENTAL
Intervention: Mydriatic digital photography
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Non-mydriatic digital photography
Number of subjects: 3611

Group type: COMPARATOR
Intervention: Technician ophthalmoscopy
Number of subjects: 3611
Study: 10225667

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Stretch Gymnastics (RMSG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing (DB)
Number of subjects: 16
Study: 8690809

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High glucagon with insulin and GH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AA infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Addition of GH and insulin
Number of subjects: 6
Study: 2009148

Group type: EXPERIMENTAL
Intervention: Delapril (15 mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril (18.75 mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (2.5 mg single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Delapril (30 mg/day for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril (37.5 mg/day for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (5 mg/day for 1 week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Delapril (4 weeks treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril (4 weeks treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (4 weeks treatment)
Number of subjects: 20
Study: 6800465

Group type: EXPERIMENTAL
Intervention: 1250 APTT units of low‐molecular‐weight heparin every 12 hours
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1850 APTT units of low‐molecular‐weight heparin as a single injection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Equal amounts of low‐molecular‐weight heparin and unfractionated heparin
Number of subjects: 150
Study: 31812557

Group type: EXPERIMENTAL
Intervention: Lunch foods presented at breakfast time (incongruous meal context)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Breakfast foods at lunch (incongruous meal context)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Breakfast foods at breakfast time (congruous meal context)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lunch foods at lunch time (congruous meal context)
Number of subjects: 40
Study: 31345973

Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Number of subjects: 273
Study: 28591280

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections into the orbicularis muscle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 26602423

Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product (15 g protein/150 g)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (3 g protein/150 g)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product (higher protein group)
Number of subjects: 62
Study: 24337761

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day for 15 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21855271

Group type: EXPERIMENTAL
Intervention: Proximal surface treatment with hydroxyapatite coating
Number of subjects: 55

Group type: COMPARATOR
Intervention: Proximal surface treatment without hydroxyapatite coating
Number of subjects: 55
Study: 19170905

Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) septal pacing
Number of subjects: 100
Study: 17445337

Group type: EXPERIMENTAL
Intervention: NCEP step II diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 44
Study: 15453897

Group type: EXPERIMENTAL
Intervention: Pelvic floor training with home biofeedback
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pelvic floor training alone
Number of subjects: 35
Study: 11235062

Group type: EXPERIMENTAL
Intervention: Natural progesterone creams
Number of subjects: 0
Study: 9683116

Group type: EXPERIMENTAL
Intervention: Geragogy-based medication instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual preprinted discharge instructions with handwritten medication information
Number of subjects: 60
Study: 8210018

Group type: COMPARATOR
Intervention: Halothane anaesthesia (group I n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia (group 2 n = 12)
Number of subjects: 24
Study: 2810090

Group type: EXPERIMENTAL
Intervention: 7 mm intraocular lens without positioning holes
Number of subjects: 550

Group type: COMPARATOR
Intervention: 7 mm intraocular lens with positioning holes
Number of subjects: 550

Group type: COMPARATOR
Intervention: Partial depth holes
Number of subjects: 550
Study: 52209

Group type: EXPERIMENTAL
Intervention: Health educational measures that motivate patients towards personal activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive forms of health education (information, instruction, demonstration)
Number of subjects: 0
Study: 31657838

Group type: EXPERIMENTAL
Intervention: Fraud FAPs
Number of subjects: 8204

Group type: EXPERIMENTAL
Intervention: Patient harm FAPs
Number of subjects: 8204

Group type: EXPERIMENTAL
Intervention: Revoked license FAPs
Number of subjects: 8204
Study: 29391150

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulsatile flow
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpulsatile flow
Number of subjects: 20
Study: 27760062

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Cognitive Behavioral Therapy (CBT)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Seal Oil
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Soy Oil
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control (BI)
Number of subjects: 413
Study: 24481483

Group type: EXPERIMENTAL
Intervention: 0 medications
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: 1 medication
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: 2 medications
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: 3 medications
Number of subjects: 603
Study: 22489518

Group type: EXPERIMENTAL
Intervention: Spinal manipulation treatment assisted with orthopedic footwear
Number of subjects: 44

Group type: COMPARATOR
Intervention: Spinal manipulation treatment only (Control)
Number of subjects: 44
Study: 20857329

Group type: EXPERIMENTAL
Intervention: High risk neighborhood environments
Number of subjects: 384

Group type: COMPARATOR
Intervention: Low risk neighborhood environments
Number of subjects: 384
Study: 17594680

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15454356

Group type: EXPERIMENTAL
Intervention: 8-month combined dietary and breast health intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group receiving mailed health education material
Number of subjects: 256
Study: 11673330

Group type: EXPERIMENTAL
Intervention: Microdysgenesis features in patients with seizure-free outcome (Class I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White matter ND
Number of subjects: 0
Study: 9675742

Group type: EXPERIMENTAL
Intervention: Hospital-based mass screening for AAA with revised appointment and reinvitation of non-responders.
Number of subjects: 4404
Study: 7926297

Group type: EXPERIMENTAL
Intervention: Antibodies to 37k antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies to GAD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD antibody levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IAAs
Number of subjects: 0
Study: 2574190

Group type: EXPERIMENTAL
Intervention: 100 mg nizatidine every 8 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: 150 mg nizatidine every 12 hours
Number of subjects: 10
Study: 15523485

Group type: EXPERIMENTAL
Intervention: Caloric restriction diet for 10 weeks
Number of subjects: 20
Study: 31242931

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h of stroke onset and continued for 24 h
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1400
Study: 28396516

Group type: EXPERIMENTAL
Intervention: D. genkwa root extractive
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (without D. genkwa extractive)
Number of subjects: 60
Study: 26522892

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 10mg (0.4mL) of bevacizumab
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin (6mg/m²)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combined treatment: subconjunctival injection of bevacizumab followed by photodynamic therapy 7 days later
Number of subjects: 7
Study: 23537173

Group type: EXPERIMENTAL
Intervention: Photoaging information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV photo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both photoaging information and UV photo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photoaging information and UV photo
Number of subjects: 0
Study: 21193187

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 114
Study: 20128319

Group type: EXPERIMENTAL
Intervention: Cervitec Plus varnish
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cervitec varnish
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both varnishes
Number of subjects: 58
Study: 16179819

Group type: EXPERIMENTAL
Intervention: Cotton Bract Extract (CBE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cotton Dust Extract (CDE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methacholine (MCh) response
Number of subjects: 21
Study: 15139567

Group type: EXPERIMENTAL
Intervention: Respimat SMI 20/50 (IB 20 microg/FEN 50 microg)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Respimat SMI 10/25 (IB 10 microg/FEN 25 microg)
Number of subjects: 892

Group type: COMPARATOR
Intervention: CFC-MDI 40/100 (IB 20 microg/FEN 50 microg)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo (Respimat SMI)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo (CFC-MDI)
Number of subjects: 892
Study: 11284817

Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg.kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg.kg‐1
Number of subjects: 20
Study: 9253097

Group type: EXPERIMENTAL
Intervention: Conventional training program
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: TerapiMaster training program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Both training programs
Number of subjects: 153
Study: 8516520

Group type: EXPERIMENTAL
Intervention: Midazolam (0.13 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg)
Number of subjects: 26
Study: 2434789

Group type: EXPERIMENTAL
Intervention: Amrinone (800, 1,600, or 3,200 micrograms/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine (200, 400, or 800 micrograms/kg/h)
Number of subjects: 20
Study: 29352425

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (80 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 54
Study: 27496096

Group type: EXPERIMENTAL
Intervention: Combined intervention (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy plus medical treatment with slow release bupropion)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Brief advice (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (just TB medical treatment)
Number of subjects: 210
Study: 24268677

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Bl‐04 2.0 × 10(9) CFU per day
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi‐07 5 × 10(9) CFU each per day
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: NCFM & Bi‐07 group
Number of subjects: 465
Study: 21885174

Group type: EXPERIMENTAL
Intervention: Paricalcitol, 1 or 2 μg/d for 16 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ergocalciferol, 50,000 units titrated to achieve serum levels ≥30 ng/mL for 16 weeks
Number of subjects: 80
Study: 20432110

Group type: EXPERIMENTAL
Intervention: Decision aid for prostate cancer screening
Number of subjects: 200

Group type: COMPARATOR
Intervention: No exposure to decision aid (Control)
Number of subjects: 200
Study: 25159905

Group type: EXPERIMENTAL
Intervention: Intervention techniques delivered in ProActive
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Participant talk during intervention
Number of subjects: 365
Study: 14711888

Group type: EXPERIMENTAL
Intervention: 2 mL glucose 30%
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 0.4 mL glucose 30%
Number of subjects: 58

Group type: COMPARATOR
Intervention: 2 mL water (control)
Number of subjects: 58
Study: 11376913

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into the masseter muscle
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into the anterior tibialis muscle
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Perceived area of experimental masseter pain
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) in the masseter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) in the anterior tibialis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heat pain thresholds (HPTs) in the masseter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heat pain thresholds (HPTs) in the anterior tibialis
Number of subjects: 22
Study: 9246149

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg BID
Number of subjects: 402

Group type: COMPARATOR
Intervention: ondansetron 8 mg TID
Number of subjects: 402
Study: 8432921

Group type: EXPERIMENTAL
Intervention: Intradermal injections of allergen-antibody complexes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 3109461

Group type: EXPERIMENTAL
Intervention: Intravenous mesna (800 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral mesna (800 mg)
Number of subjects: 6
Study: 30721390

Group type: EXPERIMENTAL
Intervention: Jet nebulizer (JN)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nebulizer integrated in high flow nasal cannulas (NHF)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NIPE monitoring
Number of subjects: 14
Study: 29800034

Group type: EXPERIMENTAL
Intervention: Recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n=77)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recombinant human pentraxin 2
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 26691411

Group type: EXPERIMENTAL
Intervention: Moderate aquatic exercise for 80 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Calm sitting position for 80 minutes
Number of subjects: 35
Study: 24166586

Group type: EXPERIMENTAL
Intervention: 10 mg Adefovir plus 100 mg Lamivudine (combination therapy)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 10 mg Adefovir (monotherapy)
Number of subjects: 122
Study: 22108629

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20661939

Group type: EXPERIMENTAL
Intervention: 10‐g Semmes‐Weinstein monofilament and 128‐Hz tuning fork examinations
Number of subjects: 1193
Study: 17131307

Group type: EXPERIMENTAL
Intervention: 16-detector multi-slice computed tomography screening
Number of subjects: 15428

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 15428
Study: 15227760

Group type: EXPERIMENTAL
Intervention: Web-based instruction (5 hours) and classroom curriculum (10 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard school curriculum nutrition education
Number of subjects: 0